<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795495</url>
  </required_header>
  <id_info>
    <org_study_id>IRB13-0036</org_study_id>
    <secondary_id>Active</secondary_id>
    <nct_id>NCT01795495</nct_id>
  </id_info>
  <brief_title>Methadone vs Magnesium in Spinal Fusion</brief_title>
  <official_title>Analgesia Following Posterior Spinal Fusion: Methadone vs Magnesium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Significant pain may occur following posterior spinal fusion despite the use of
      conventionally accepted techniques including patient controlled analgesia. If detected, a
      significant reduction in opioid requirements may lead to improved patient satisfaction and
      decreased opiate side effects.

      The current study would use a prospective, randomized trial investigating the efficacy of one
      of 2 regimens as adjuncts to intraoperative anesthesia and postoperative analgesia, along
      with a third control group. The patients would be randomized to receive remifentanil plus a
      single intraoperative dose of methadone; remifentanil plus a bolus followed by an infusion of
      magnesium; or remifentanil alone. In addition, the two medications being studied might make
      it easier to determine the efficacy of neurophysiologic monitoring including somatosensory
      evoked potential (SSEP) (amplitude and latency) and motor evoked potential (MEP) (mA)
      required to elicit the response.

      The purpose of this study would be to explore the effects of intraoperative methadone vs
      magnesium on intraoperative anesthetic requirements, postoperative opioid requirements, the
      efficacy of neurophysiologic monitoring including SSEP and MEP, inspired concentration of
      desflurane, remifentanil, and the need for intraoperative supplemental agents to control
      blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra- and Post-operative Pain Relief</measure>
    <time_frame>Intra-operative and 24 hours post-operatively</time_frame>
    <description>To prospectively compare the effects of intra-operative methadone and magnesium on postoperative opioid requirements. Total amount of hydromorphone administered in OR, recovery room (PACU), and on the inpatient ward 24 hours post-operatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Scores</measure>
    <time_frame>Post-operatively to 24 hours</time_frame>
    <description>VAS pain score - 0 being no pain and 10 being worst pain.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Idiopathic Scoliosis</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive remifentanil alone as is the current practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil plus methadone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil plus magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone hydrochloride</intervention_name>
    <description>This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia</description>
    <arm_group_label>Remifentanil plus methadone</arm_group_label>
    <other_name>Methadone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).</description>
    <arm_group_label>Remifentanil plus magnesium</arm_group_label>
    <other_name>Magnesium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <arm_group_label>Remifentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 12, and younger than 19 years of age undergoing posterior spinal
             fusion for idiopathic scoliosis

          -  American Society of Anesthesiologist (ASA) physical status I or II

          -  Parents/Guardian willing and able to authorize informed consent

          -  Patients willing and able to authorize assent

        Exclusion Criteria:

          -  Patients presenting with neuromuscular scoliosis

          -  Patients deemed at increased risk of adverse reactions due to the presence of
             pre-existing severe organ system dysfunction, including debilitating lung disease,
             severe obstructive sleep apnea, severe congenital or acquired heart disease, and/or
             severe renal impairment

          -  Patients who are both being currently treated for a psychological disorder and have a
             history of hospitalization for said disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P. Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stemland CJ, Witte J, Colquhoun DA, Durieux ME, Langman LJ, Balireddy R, Thammishetti S, Abel MF, Anderson BJ. The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. Paediatr Anaesth. 2013 Jan;23(1):51-7. doi: 10.1111/pan.12021. Epub 2012 Sep 14.</citation>
    <PMID>22978825</PMID>
  </reference>
  <reference>
    <citation>Sharma A, Tallchief D, Blood J, Kim T, London A, Kharasch ED. Perioperative pharmacokinetics of methadone in adolescents. Anesthesiology. 2011 Dec;115(6):1153-61. doi: 10.1097/ALN.0b013e318238fec5.</citation>
    <PMID>22037641</PMID>
  </reference>
  <reference>
    <citation>Gottschalk A, Durieux ME, Nemergut EC. Intraoperative methadone improves postoperative pain control in patients undergoing complex spine surgery. Anesth Analg. 2011 Jan;112(1):218-23. doi: 10.1213/ANE.0b013e3181d8a095. Epub 2010 Apr 24.</citation>
    <PMID>20418538</PMID>
  </reference>
  <reference>
    <citation>Elsharnouby NM, Elsharnouby MM. Magnesium sulphate as a technique of hypotensive anaesthesia. Br J Anaesth. 2006 Jun;96(6):727-31. Epub 2006 May 2.</citation>
    <PMID>16670112</PMID>
  </reference>
  <reference>
    <citation>Levaux Ch, Bonhomme V, Dewandre PY, Brichant JF, Hans P. Effect of intra-operative magnesium sulphate on pain relief and patient comfort after major lumbar orthopaedic surgery. Anaesthesia. 2003 Feb;58(2):131-5.</citation>
    <PMID>12562408</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <results_first_submitted>December 11, 2017</results_first_submitted>
  <results_first_submitted_qc>February 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2018</results_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>David P. Martin</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Spinal Fusion</keyword>
  <keyword>Scoliosis</keyword>
  <keyword>Methadone</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Back Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Remifentanil</title>
          <description>This arm will receive remifentanil alone as is the current practice.
Remifentanil</description>
        </group>
        <group group_id="P2">
          <title>Remifentanil Plus Methadone</title>
          <description>This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
Methadone hydrochloride: This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia</description>
        </group>
        <group group_id="P3">
          <title>Remifentanil Plus Magnesium</title>
          <description>This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
Magnesium Sulfate: This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Remifentanil</title>
          <description>This arm will receive remifentanil alone as is the current practice.
Remifentanil</description>
        </group>
        <group group_id="B2">
          <title>Remifentanil Plus Methadone</title>
          <description>This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
Methadone hydrochloride: This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia</description>
        </group>
        <group group_id="B3">
          <title>Remifentanil Plus Magnesium</title>
          <description>This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
Magnesium Sulfate: This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="1.4"/>
                    <measurement group_id="B2" value="15.4" spread="1.2"/>
                    <measurement group_id="B3" value="15.3" spread="1.9"/>
                    <measurement group_id="B4" value="15.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.6" spread="4.3"/>
                    <measurement group_id="B2" value="22.8" spread="5.7"/>
                    <measurement group_id="B3" value="24.2" spread="5.6"/>
                    <measurement group_id="B4" value="22.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intra- and Post-operative Pain Relief</title>
        <description>To prospectively compare the effects of intra-operative methadone and magnesium on postoperative opioid requirements. Total amount of hydromorphone administered in OR, recovery room (PACU), and on the inpatient ward 24 hours post-operatively.</description>
        <time_frame>Intra-operative and 24 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remifentanil</title>
            <description>This arm will receive remifentanil alone as is the current practice.
Remifentanil</description>
          </group>
          <group group_id="O2">
            <title>Remifentanil Plus Methadone</title>
            <description>This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
Methadone hydrochloride: This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Remifentanil Plus Magnesium</title>
            <description>This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
Magnesium Sulfate: This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).</description>
          </group>
        </group_list>
        <measure>
          <title>Intra- and Post-operative Pain Relief</title>
          <description>To prospectively compare the effects of intra-operative methadone and magnesium on postoperative opioid requirements. Total amount of hydromorphone administered in OR, recovery room (PACU), and on the inpatient ward 24 hours post-operatively.</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.11"/>
                    <measurement group_id="O2" value="0.26" spread="0.1"/>
                    <measurement group_id="O3" value="0.38" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Pain Scores</title>
        <description>VAS pain score - 0 being no pain and 10 being worst pain.</description>
        <time_frame>Post-operatively to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remifentanil</title>
            <description>This arm will receive remifentanil alone as is the current practice.
Remifentanil</description>
          </group>
          <group group_id="O2">
            <title>Remifentanil Plus Methadone</title>
            <description>This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
Methadone hydrochloride: This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Remifentanil Plus Magnesium</title>
            <description>This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
Magnesium Sulfate: This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Scores</title>
          <description>VAS pain score - 0 being no pain and 10 being worst pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.2"/>
                    <measurement group_id="O2" value="5.1" spread="1.8"/>
                    <measurement group_id="O3" value="5.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Remifentanil</title>
          <description>This arm will receive remifentanil alone as is the current practice.
Remifentanil</description>
        </group>
        <group group_id="E2">
          <title>Remifentanil Plus Methadone</title>
          <description>This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
Methadone hydrochloride: This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia</description>
        </group>
        <group group_id="E3">
          <title>Remifentanil Plus Magnesium</title>
          <description>This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
Magnesium Sulfate: This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Martin, MD</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>6147224200</phone>
      <email>David.Martin@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

